Journal of Antimicrobial Chemotherapy (2000) 45, 493-501
© 2000 The British Society for Antimicrobial Chemotherapy
Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia
a Service of Infectious Diseases and b Service of Microbiology, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot s/n, 41013 Seville; c Pathology Department, Hospital Universitario Carlos Haya, Camino de Antequera s/n, 29010 Malaga, Spain
Acinetobacter baumannii is a common cause of nosocomial pneumonia and other nosocomial infections. Multiresistant A. baumannii has also a high prevalence, which can make effective treatment difficult. We designed a new model of A. baumannii experimental pneumonia using C57BL/6 immunocompetent mice. This model was used to compare the efficacy of imipenem, doxycycline and amikacin in monotherapy, and the combination of imipenem plus amikacin and doxycycline plus amikacin. Doxycycline plus amikacin were synergic in vitro after 24 h incubation, whereas imipenem plus amikacin showed no in vitro synergy. The number of sterile lungs and the lung clearance of A. baumannii were greater in the group treated with imipenem than in those treated with amikacin or doxycycline in monotherapy (P < 0.05). The combination of imipenem plus amikacin and doxycycline plus amikacin was no more effective than imipenem alone in the clearance of organisms from lungs (2.42 ± 1.46 cfu/g versus 2.7 ± 1.5 cfu/g versus 1.23 ± 1.02 cfu/g). These results suggest that the addition of amikacin does not improve the results obtained by imipenem monotherapy. Doxycycline plus amikacin is an alternative to imipenem in the therapy of A. baumannii pneumonia.
* Corresponding author. Tel: +34-5-4248029; Fax: +34-5-4240636; E-mail: rodher{at}cica.es
Present address. Hospital Punta de Europa, Algeciras, Cádiz, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Beceiro, R. Lopez-Rojas, J. Dominguez-Herrera, F. Docobo-Perez, G. Bou, J. Pachon, and the Spanish Network for Research in Infectious Dis In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4298 - 4304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Russo, J. M. Beanan, R. Olson, U. MacDonald, N. R. Luke, S. R. Gill, and A. A. Campagnari Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology Infect. Immun., August 1, 2008; 76(8): 3577 - 3586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pachon-Ibanez, F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam J. Antimicrob. Chemother., September 1, 2006; 58(3): 689 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pichardo, J. M. Rodriguez-Martinez, M. E. Pachon-Ibanez, C. Conejo, J. Ibanez-Martinez, L. Martinez-Martinez, J. Pachon, and A. Pascual Efficacy of Cefepime and Imipenem in Experimental Murine Pneumonia Caused by Porin-Deficient Klebsiella pneumoniae Producing CMY-2 {beta}-Lactamase Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3311 - 3316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model J. Antimicrob. Chemother., December 1, 2004; 54(6): 1085 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jain and L. H Danziger Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Higgins, H. Wisplinghoff, D. Stefanik, and H. Seifert In Vitro Activities of the {beta}-Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam Alone or in Combination with {beta}-Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter baumannii Strains Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1586 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol Efficacy of Colistin versus {beta}-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1946 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Rodriguez-Hernandez, L. Cuberos, C. Pichardo, F. J. Caballero, I. Moreno, M. E. Jimenez-Mejias, A. Garcia-Curiel, and J. Pachon Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains J. Antimicrob. Chemother., April 1, 2001; 47(4): 479 - 482. [Abstract] [Full Text] [PDF]
|
|